The Problem MELD Was Designed to Solve
Before MELD, liver transplant allocation in the United States was determined primarily by waiting time and geographic region — a system that rewarded patience, not medical urgency. The result: patients died on the waitlist while others with less severe disease received organs. A sicker-first, objective, lab-based system was needed.
Origins: The TIPS Study (1999–2000)
The MELD score was originally developed by Malinchoc et al. at the Mayo Clinic in 2000 to predict 3-month survival in patients undergoing transjugular intrahepatic portosystemic shunt (TIPS) placement — not for transplant allocation. The model identified three readily available lab values as the strongest predictors of short-term mortality in patients with end-stage liver disease:
- Serum creatinine (reflects renal function, a major prognostic driver)
- Total bilirubin (reflects synthetic and excretory function)
- INR (reflects synthetic function — coagulation factor production)
MELD Adopted for Transplant Allocation (2002)
UNOS adopted the MELD score for liver transplant allocation in February 2002, replacing the Child-Pugh and waiting-time based system. This was a landmark shift: organs would go to the sickest patients first, as defined by an objective, validated, lab-based score.
The original MELD formula:
MELD = 3.78 × ln[bilirubin (mg/dL)]
+ 11.2 × ln[INR]
+ 9.57 × ln[creatinine (mg/dL)]
+ 6.43
Score range: 6–40. Each point increase corresponds to approximately a 10% increase in 3-month mortality. Creatinine is capped at 4.0 mg/dL; minimum values for each variable set at 1.0 to avoid negative logarithms.
MELD-Na (2016)
Hyponatremia (low serum sodium) is a powerful independent predictor of waitlist mortality in cirrhotic patients, capturing the severity of splanchnic vasodilation and neurohormonal activation beyond what creatinine alone reflects. Multiple studies showed MELD significantly underestimated waitlist mortality in hyponatremic patients.
UNOS adopted MELD-Na in January 2016:
MELD-Na = MELD
+ 1.32 × (137 − Na)
− [0.033 × MELD × (137 − Na)]
Sodium is constrained to 125–137 mEq/L in the formula. MELD-Na became the official allocation score in the US. Patients with low sodium and otherwise similar MELD scores moved up the waitlist.
MELD 3.0 (2022)
Analysis of national transplant registry data revealed that women had higher waitlist mortality at equivalent MELD-Na scores compared to men — a consequence of systematic disadvantages in the formula including lower baseline creatinine values (masking renal impairment) and the biology of ascites accumulation. Women were less likely to be transplanted and more likely to die waiting.
UNOS adopted MELD 3.0 in August 2022:
MELD 3.0 = 1.33 × (female sex [1 if female, 0 if male])
+ [4.56 × ln(bilirubin)]
+ [0.82 × (137 − Na)] − [0.24 × (137 − Na) × ln(creatinine)]
+ [9.09 × ln(INR)]
+ [11.14 × ln(creatinine)]
+ 7
Key changes from MELD-Na: added 1.33-point bonus for female sex, incorporated serum albumin as a modifier (captures malnutrition and synthetic function not captured by bilirubin/INR alone), updated coefficients from a larger and more contemporary dataset.
Clinical Interpretation
- MELD 3.0 <10: Low mortality risk; typically managed medically, transplant not yet indicated
- MELD 3.0 10–18: Moderate risk; transplant evaluation should begin
- MELD 3.0 >18: Significant 3-month mortality risk; priority for organ allocation
- MELD 3.0 >25: High urgency; risk of waitlist mortality without transplantation
Note: MELD applies to allocation for chronic liver disease. Status 1A/1B designations exist for acute liver failure cases that bypass MELD-based allocation entirely due to immediacy of death without transplantation.